AGENUS INC Long-Lived Assets
AGENUS INC (AGEN) had Long-Lived Assets of $18.78 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Segment Reporting
us-gaap:NoncurrentAssets · last filed 2026-03-16
- 2025-12-31: Long-Lived Assets $18.78M.
- 2024-12-31: Long-Lived Assets $125.92M.
- 2023-12-31: Long-Lived Assets $142.76M.
- 2022-12-31: Long-Lived Assets $137.47M.
| Period end | Long-Lived Assets | Long-Lived Assets as first filed |
|---|---|---|
| 2025-12-31 | $18.78M 10-K · filed 2026-03-16 | |
| 2024-12-31 | $125.92M 10-K · filed 2026-03-16 | |
| 2023-12-31 | $142.76M 10-K · filed 2025-03-17 | |
| 2022-12-31 | $137.47M 10-K · filed 2024-03-14 | |
| 2021-12-31 | $69.57M 10-K · filed 2023-03-16 | |
| 2020-12-31 | $30.91M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $27.74M 10-K · filed 2021-03-16 | |
| 2018-12-31 | $26.33M 10-K · filed 2020-03-16 | |
| 2017-12-31 | $27.39M 10-K · filed 2019-03-18 | |
| 2016-12-31 | $26.92M 10-K · filed 2018-03-16 | |
| 2015-12-31 | $16.58M 10-K · filed 2017-03-16 | |
| 2014-12-31 | $7.21M 10-K · filed 2016-03-15 | $7.00M 10-K · filed 2015-03-16 |
| 2013-12-31 | $4.09M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |